Novo Nordisk’s diabetes drug Ozempic may reduce the risk of Alzheimer’s disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in
Read More
Weight management
Ozempic is driving up the cost of your health care, whether you can get your hands on it or not
Health-care costs are going up, and yet workers may still not get the coverage they want — particularly when it
Read More
This ETF is trying to satisfy appetites for weight loss stocks
Tema ETFs is behind the GLP-1, Obesity & Cardiometabolic ETF (HRTS), which is up 26% since its inception last November.
Read More
Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that
Read More
Weight loss drug Wegovy is now approved for heart health — but that won’t mean broad insurance coverage just yet
Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say
Read More
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize
Read More
Eli Lilly’s direct drug sales alone may not upend the industry, but others could follow suit
LillyDirect is the latest attempt to simplify what critics call a complex system for distributing, pricing and prescribing prescription drugs.
Read More
The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead
2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance
Read More
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug,
Read More